Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced a significant milestone in its ongoing Phase 2 clinical study, ACTIVATE (clinicaltrials ...
Compugen’s Unigen AI/ML platform drives the discovery of potentially novel checkpoints. Find out what nudges me to rate CGEN ...
Forlong Biotechology inks agreement with Shanghai Henlius Biotech to develop cancer immunotherapy: Shanghai Friday, October 24, 2025, 17:00 Hrs [IST] Forlong Biotechnology, a clin ...
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...
The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that it has entered into a ...
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while ...
Crypto.com secures UAE Central Bank approval to enable government payments in crypto, paving way for dirham-based digital ...
xMoney, the compliant, all-in-one payment ecosystem bridging traditional finance and Web3, has officially launched its native ...
Deutsche Börse AG ( OTCPK:DBOEF) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT ...
Kusile Unit 6 is now commercially active, finally breaking the 17 year curse that caused delays in its power station.
For Satyajit Banerjee of GrownUpTales, finance is storytelling, not jargon. The finfluencer believes new creators should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback